d3-T is a Novel, Non-Aromatizing Androgen, Offering the Benefits of Testosterone Without Converting to Estradiol Addressing a Known Breast Cancer Risk CONCORD, Mass.--(BUSINESS WIRE)--Aviva Biopharm ...

In its feedback, the FDA acknowledged the potential breast cancer risk associated with T use in women—a central safety issue that has historically limited the development of a T therapy for women.

Matt Kaeberlein, a longevity researcher, started TRT in his 50s. He said stigma and lack of information can make the process confusing.

CONCORD, Mass., January 26, 2026--(BUSINESS WIRE)--Aviva Bio, a new biotechnology company focused on rewriting the narrative around hormone-based medicine, announced today it has received formal ...